The stock of Arbutus Biopharma Corporation (NASDAQ:ABUS) registered an increase of 1.37% in short interest. ABUS’s total short interest was 1.37 million shares in September as published by FINRA. Its up 1.37% from 1.35M shares, reported previously. With 76,300 shares average volume, it will take short sellers 18 days to cover their ABUS’s short positions. The short interest to Arbutus Biopharma Corporation’s float is 7.4%. About 7,061 shares traded hands. Arbutus Biopharma Corp (NASDAQ:ABUS) has risen 28.97% since February 8, 2016 and is uptrending. It has outperformed by 12.48% the S&P500.
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The company has a market cap of $205.50 million. The Firm is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection , a disease of the liver caused by the hepatitis B virus (HBV). It currently has negative earnings. It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology.
Out of 3 analysts covering Arbutus Biopharma Corporation (NASDAQ:ABUS), 1 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 33% are positive. Arbutus Biopharma Corporation has been the topic of 6 analyst reports since October 29, 2015 according to StockzIntelligence Inc. Leerink Swann downgraded the stock on August 5 to “Market Perform” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.